about
Low-molecular-weight heparins in the treatment of venous thromboembolismStrategies to Overcome Heparins' Low Oral BioavailabilityTransitions in the Prophylaxis, Treatment and Care of Patients with Venous ThromboembolismUpdate on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current EvidenceMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewA systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiencyParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe potential benefits of low-molecular-weight heparins in cancer patientsA peptide found by phage display discriminates a specific structure of a trisaccharide in heparin.The effect of dalteparin versus unfractionated heparin on the levels of troponin I and creatine kinase isoenzyme MB in elective percutaneous coronary intervention: a multicenter studyTreatment of a patient with an undefined hypercoagulable state with long-term low-molecular-weight heparin.Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.Synthesis and anticoagulant activity of polyureas containing sulfated carbohydratesCost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacementPolysulfated trehalose as a novel anticoagulant agent with dual mode of action.Low-molecular-weight heparin and abciximab for thrombo-occlusive saphenous vein graft disease. Report of 2 cases.Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.Effect of low molecular weight heparin (enoxaparin) on congenital cataract surgeryPharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and childrenModulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivoAn internal deletion enhances the transcriptional activity of a recombinant retrovirus in hematopoietic cells in vivo.Control of anticoagulant and antiplatelet therapy. Managing patients with acute thrombotic disorders.Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cellsBioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers.The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task ForceUse of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells.Audit of anticoagulation after embolectomy for acute ischaemia.Tailored glycopolymers as anticoagulant heparin mimetics.Electrophoresis for the analysis of heparin purity and quality.How We Manage Pediatric Deep Venous Thrombosis.Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations.Novel antithrombotic therapy.Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosisPlatelet aggregation in humans and nonhuman primates: relevance to xenotransplantation.Biomarkers of Coagulation and Fibrinolysis during Cemented Total Hip Arthroplasty with Pre- versus Postoperative Start of Thromboprophylaxis.B-Cell lymphoma presenting as mechanical low-back pain with leg pain: the importance of the physical and ultrasound examination of the buttock in patients with low-back and leg pain: a case report.Population pharmacokinetics of enoxaparin in early stage of pediatric liver transplantation.Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?Anticoagulation in venous thrombosis.
P2860
Q24792692-F9E06264-8AB3-45BD-8F4F-BB12C7E7C8B5Q26745571-B30A63EB-BF1F-4ED6-AC03-78D1F73622B0Q26775157-12A182ED-6F12-4EC6-B7FB-A14C824F7D97Q26782483-D819ECB4-0C85-47E7-A850-C12D50CC449DQ26992262-07FAAC8B-B598-4EDF-9C26-A039C1B4C7DBQ26995027-34F88DB5-89C4-4FC8-8763-D24FED65FBBFQ33399576-18EA83CB-42F9-458E-B141-3FD6DDBD423BQ33698360-8D2438EF-418D-4B10-B763-E25B33AF2024Q33824892-CD99F2EB-6A98-4BB5-A0F8-1ECB6F035425Q34171176-C0ECC498-9B63-407C-A778-31A691EB6E7BQ34183316-922FA486-1FB2-4822-9A54-15C8B05D68F8Q34610484-6F3D9F8E-CA98-4384-BA52-4FEEC582AAC8Q34669693-1CFF6885-01CC-4965-8DB0-9F669C96224AQ34708293-F235F882-4F46-4B29-BF65-0286B2D2ACBEQ35239901-4858A6C6-D4ED-49AB-9579-C1BC50571681Q35663721-573DC95F-3151-45BC-B682-15E8303E70A5Q35826839-595B10C7-7035-467F-A748-D226574ABFDEQ36358625-4822452C-E3F3-45CA-8404-1F2B16E4C1E7Q36510063-F4D645DA-04AF-40A6-9F7D-04B85E38D42BQ36611135-85B098C2-905A-4282-B07B-1B6AD08F378AQ36636798-537B612D-4933-43D6-81D2-B4D344817172Q36652525-D1D7EEBC-0C50-41AF-B0D1-DD03D4601869Q36842690-8DFCE5C8-A857-4D5F-AC06-EF69F2380297Q37077188-1000536C-ABAE-4273-B0D9-0D48BECBA8B5Q37232098-4C0951FA-4FF0-4C09-B883-B8F74F82969AQ37243800-C1C07B10-2DB5-4C43-8B66-E9BE42C8B6C0Q37532738-4EC78BD5-FEB5-4B0B-8888-A7A8C456A6DAQ37619706-361FF81A-2674-4EFE-9489-4E7D3FA70FE0Q38021961-82D5AFEF-5F5F-469C-A971-0F45A81A9CA1Q38926114-E3A08F1C-AB49-4E4A-82FD-85E2AD437B82Q39359007-833652ED-4A9A-4189-9B67-D542B1C8FF1AQ39861279-60FE8507-1653-47B8-8726-D8BA85DECF39Q40725160-034C22F3-436E-49C6-BE8F-810F04DB4A2CQ41821940-97E53131-6C97-46DE-9391-AEF3956D46A0Q42320921-B134B5B7-E07C-40FC-B95C-14E463F3D6B3Q42767676-425295A1-91BD-4926-9CDE-326296E17848Q45899561-2FE43EC1-9566-415D-9414-C6E550A2D491Q50052116-2D36F96F-9371-45FC-8C80-D2C8C3328BF8Q50323429-94ACDC0B-0FA9-45D6-BA8B-D6938C09F806Q53364514-E08FC3F7-6CA2-4B89-87E9-3D92A15E03E3
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Low molecular weight heparin.
@ast
Low molecular weight heparin.
@en
type
label
Low molecular weight heparin.
@ast
Low molecular weight heparin.
@en
prefLabel
Low molecular weight heparin.
@ast
Low molecular weight heparin.
@en
P1433
P1476
Low molecular weight heparin.
@en
P2093
P407
P577
1992-01-01T00:00:00Z